<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Lori</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Armitage, Jane</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">HPS2-THRIVE Results</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">27-28</style></pages><abstract><style  face="normal" font="default" size="100%">Approximately two thirds of patients can tolerate extended-release niacin when combined with laropiprant, according to a prespecified interim safety and tolerability analysis of the Heart Protection Study 2: Treatment of HDL to Reduce the Incidence of Vascular Events [HPS2-THRIVE; NCT00461630] study. The addition of niacin/laropiprant to statin therapy offers a dual goal of decreasing low-density lipoprotein-cholesterol and increasing high-density lipoprotein-cholesterol.</style></abstract><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>